Keyphrases
Netherlands
100%
Adult Patients
100%
Standard of Care
100%
Cost-effectiveness
100%
Chronic Kidney Disease
100%
Empagliflozin
100%
Quality-adjusted Life Years
36%
Kidney
27%
Kidney Disease Progression
18%
Dutch
9%
Published Data
9%
Cost Savings
9%
Sensitivity Analysis
9%
Microsimulation Model
9%
Cost-effectiveness Analysis
9%
Treatment Effect
9%
Health Benefits
9%
Disease Progression
9%
Societal Perspective
9%
Probabilistic Sensitivity Analysis
9%
Incremental Cost-effectiveness Ratio
9%
Albuminuria
9%
Baseline Characteristics
9%
Population Mortality
9%
Chronic Kidney Disease Patients
9%
Pharmacoeconomic Guidelines
9%
Willingness-to-pay Threshold
9%
Total Saving
9%
Utility Data
9%
Model Simulating
9%
Diabetes Status
9%
Total Discounted Cost
9%
Markov State
9%
KDIGO Guidelines
9%
Treatment Utility
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Empagliflozin
100%
Disease Exacerbation
20%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
20%
Albuminuria
10%
Base
10%
Pharmacoeconomics
10%